Rare events in cancer recurrence timing

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Scopus citations

Abstract

Tumor recurrence due to acquired resistance to anti-cancer treatments poses a major clinical problem in treating cancer. One major cause of drug-resistance is the acquisition of random point mutations in the genomic sequence of cancer cells which confer resistant phenotypes. Despite an initial response to treatment, emergent drug-resistant subpopulations often eventually drive the recurrence and regrowth of the tumor. The timing of such cancer recurrence is highly variable in patient populations, and is governed by a balance between several factors such as initial tumor size, mutation rates, and growth kinetics of drug-sensitive and resistant cells. To better understand patterns of cancer progression in patient populations, we are interested in the mechanisms driving early or late cancer recurrences. In previous work, we modeled the dynamics of recurrence by considering escape from a subcritical branching process, where the establishment of a clone of escape mutants can lead to total population growth after the initial decline. Here, we study and characterize the rare events leading to early or late crossover time, defined as the time at which the total cancer population first becomes dominated by the emerging resistant cell population. In particular, using this model we investigate algorithms for estimating the probability of early crossover events, which are correlated with early tumor recurrence.

Original languageEnglish (US)
Title of host publicationProceedings of the 2012 Winter Simulation Conference, WSC 2012
DOIs
StatePublished - 2012
Event2012 Winter Simulation Conference, WSC 2012 - Berlin, Germany
Duration: Dec 9 2012Dec 12 2012

Publication series

NameProceedings - Winter Simulation Conference
ISSN (Print)0891-7736

Other

Other2012 Winter Simulation Conference, WSC 2012
Country/TerritoryGermany
CityBerlin
Period12/9/1212/12/12

Fingerprint

Dive into the research topics of 'Rare events in cancer recurrence timing'. Together they form a unique fingerprint.

Cite this